Cyprotex PLC Trading Update (7080O)
01 June 2015 - 4:01PM
UK Regulatory
TIDMCRX
RNS Number : 7080O
Cyprotex PLC
01 June 2015
1 June 2015
Cyprotex PLC
("Cyprotex" or the "Company" or the "Group")
Trading update
Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services
company, provides an update on profit guidance for the year to 31
December 2015
Trading update
The financial performance of the Company for the first 5 months
of the year is ahead of expectations driven by strong growth in UK
revenues and whilst there remain challenges, particularly in the US
operations, the Board expects that its full year revenues and
profits will exceed current market expectations.
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20
Cyprotex) 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors:
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites in Macclesfield, near Manchester in
the UK, Watertown, MA and Kalamazoo MI in the US. The Company was
established in 1999 and works with more than 1,100 partners within
the pharmaceutical and biotech industry, cosmetics and personal
care industry and the chemical industry. Cyprotex acquired Apredica
and the assets of Cellumen Inc. in August 2010 and the combined
business provides support for a wide range of experimental and
computational ADME-Tox and PK services, extending from early drug
discovery through to IND submission. The acquisition of the assets
and business of CeeTox in January 2014 has enabled Cyprotex to
expand its range of services to target the personal care, cosmetics
and chemical industries. The Company's core capabilities include
high quality in vitro ADME screening services, mechanistic
toxicology and high content toxicology screening services,
including our proprietary CellCiphr(R) toxicity prediction
technology, predictive modelling using PBPK and QSAR techniques,
including Cloe(R) PK for in vivo PK prediction, and a range of
skin, ocular and endocrine disruption services. For more
information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTBUGDUXXDBGUC
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cyprotex (London Stock Exchange): 0 recent articles
More Cyprotex News Articles